Skip to main content

Table 5 Cost-utility analysis for base case and additional scenarios of interest

From: Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model

Scenarios

Cervical cancer cases/deaths averteda

QALYs gaineda

Incremental costsb

ICURa

Base case HPV-16/18

1172 / 618

848

98695

116

Base case HPV-6/11/16/18

1069 / 564

819

442981

541

HPV-16/18 prevalence; 70% cervical cancer cases due HPV types 16 and 18d

1129 / 595

816

310450

381

HPV-6/11/16/18 prevalence; 70% cervical cancer cases due HPV types 16 and18d

977 / 516

751

887321

1181

HPV-16/18 with discounting 3%e

1172 / 618

3124

-10198541

dominantc

HPV-16/18 + regular screening (every 5 years interval)f

1158 / 612

833

-1970016

dominantc

HPV-16/18 with no cross-protectiong

976 / 515

703

1620610

2305

HPV-16/18 with cross-protection assumed as the lower value of 95% CI to cervical cancer (68.4%; 95% CI: 45.7 - 82.4%) [30, 31]g

1106 / 583

799

470344

589

HPV-16/18 price as in PAHO 2012 revolving fundh

1172 / 618

848

-2197687

dominantc

HPV-6/11/16/18 vaccine price as in PAHO 2012 revolving fundh

1069 / 564

819

-1582203

dominantc

HPV-6/11/16/18 vaccine with no VE to HPV types 6 and11i

1069 / 564

772

894820

1159

HPV-16/18 waning (HPV-18 & other oncogenic HPV) after 20 years of first dose /during 5yj

955 / 487

794

568274

715

HPV-16/18 waning (HPV-18 & other oncogenic HPV) after 20 years of 1st dose/during 5y + booster dose (21 years after first dose) j, k

1170 / 617

846

797020

942

HPV-16/18, 2 dose vaccine schedulel

1172 / 618

848

-2249344

dominantc

HPV-16/18 (2 doses) waning (HPV-18 & other oncogenic HPV) after 20 years of 1st dose/during 5yj, l

955 / 487

794

-1779765

dominantc

HPV-16/18 (2 doses) waning (all HPV) after 20 years of first dose/during 5y j, l

501 / 212

681

-791887

dominantc

HPV-16/18 (2 doses) waning (HPV-18 & other oncogenic HPV) after 20 years of first dose/during 5y + booster dose (21 years after first dosej, k, l

1170 / 617

846

-1551019

dominantc

HPV-16/18 (2 doses) waning (all oncogenic HPV) after 20 years of first dose/during 5y + booster dose (21 years after first dose)j, k, l

1164 / 615

841

-1507808

dominantc

  1. aCompared to no vaccination scenario; bAdditional costs compared to no vaccination scenario; cICUR is showing a cost-saving result; dBase Case: 80% prevalence; eBase case: 6% discount; fBase case: Every 3 years interval; gBase case: CIN2/3 cross protection for bivalent vaccine 68.4% and quadrivalent vaccine 32.5%; hBase case: vaccine cost per dose 20 US dollars for both vaccines –price parity-; iBase case: 98% vaccine efficacy; jBase case: Lifetime duration of vaccine efficacy; kBase case: No booster dose; lBase case: 3 doses.
  2. Note: HPV: human papillomavirus; ICUR: incremental cost-utility ratio; VE: vaccine efficacy; PAHO: Pan American Health Organization; QALY: quality-adjusted life years.
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us